CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a Phase 3 Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hem...
Phase 3
New York, New York, United States and 42 other locations
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors ...
Phase 3
Bronx, New York, United States and 17 other locations
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and...
Phase 2
Brooklyn, New York, United States and 43 other locations
Primary Objectives:To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemi...
Phase 3
New York, New York, United States and 20 other locations
A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and a...
Phase 1, Phase 2
New York, New York, United States and 8 other locations
safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease...
Phase 1
Bronx, New York, United States and 17 other locations
Primary Objective:Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).Secondary Objectives:* E...
Phase 3
New York, New York, United States and 29 other locations
CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney...
Phase 2
Stamford, Connecticut, United States and 48 other locations
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...
Phase 2
New York, New York, United States and 119 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
New York, New York, United States and 297 other locations
Clinical trials
Research sites
Resources
Legal